Trial reportOral diseases2026
Ozonized Hydrogel and Chlorhexidine Gel for Peri-Implant Mucositis: A 24-Month Randomized Controlled Trial.
Trial report in Oral diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Authors' Reply "Ozonized Hydrogel and Chlorhexidine Gel for Peri-Implant Mucositis: A 24-Month Randomized Controlled Trial".Oral diseases · 2026Article
- Comment on "Ozonized Hydrogel and Chlorhexidine Gel for Peri-Implant Mucositis: A 24-Month Randomized Controlled Trial".Oral diseases · 2026Article
- Neuro-Instructive Hydrogels - A Key to Sensory Innervation in Oral Tissues: A Comprehensive Review.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis randomized controlled trial evaluated the 24-month effectiveness of a nonsurgical intervention for peri-implant mucositis, comparing a 15% ozonated sunflower oil hydrogel with a 1% chlorhexidine gel.
methodsThirty patients with 360 peri-implant mucositis sites were treated in a split-mouth design, receiving both therapies in randomly assigned quadrants. Clinical parameters-probing pocket depth (PPD), plaque index (PI), bleeding on probing (BoP), bleeding score (BS), suppuration index (SI), and marginal mucosal condition (MMC)-were recorded at baseline and nine follow-ups. Marginal bone level (MBL) was measured radiographically at baseline, 6, 15, and 24 months. Recurrence was defined as the reappearance of BoP, SI, or MMC after resolution. Data were analyzed with the Friedman test and Dunn's post hoc.
resultsBoth treatments produced significant improvements. The ozonated hydrogel achieved faster and greater reductions in BoP, BS, and SI, with significant differences at 6 and 24 months. MBL remained stable in both groups, with no progression to peri-implantitis. No adverse events occurred, and compliance was maintained.
conclusionsThe ozonated sunflower hydrogel provided superior anti-inflammatory effects over chlorhexidine, particularly in reducing bleeding and suppuration, while preserving bone stability. Its safety, efficacy, and acceptability support its use as an adjunct in peri-implant mucositis maintenance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.